Xeltis has been selected as one of the finalists in medical technology for the 2017 Edison Awards. In the spirit of Thomas Edison, the global awards recognize persistence and excellence in innovation. Final winners will be announced at the 30th Annual Edison Awards Gala Dinner on 20 April in New York.
Xeltis’ cutting-edge RestoreX technology is the culmination of the latest progress in three separate fields: regenerative medicine, Nobel Prize-awarded supramolecular chemistry and electrospinning.
“Xeltis is pioneering a new frontier in heart valve replacement, using the latest scientific developments. We are thrilled to be acknowledged by such a prestigious innovation award, our ethos could not be more aligned with the Edison Awards.” Xeltis CEO Laurent Grandidier commented.
Learn more about the Edison Award finalist RestoreX technology here.
